GLYCOBIA, INC.

Basic Information

33 Thornwood Drive
ITHACA, NY, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 824602135
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. IGF OT IGF TOPIC CHEMICALLY DEFINED GLYCAN LIBRARIES FOR REFERENCE STANDARDS AND GLYCOMICS RESEARCH JOINT NCI NIGMS PROGRAM

    Amount: $999,898.00

    Not Available

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. Glycoconjugate therapeutic peptides for improved treatment of human diseases

    Amount: $636,906.00

    DESCRIPTION provided by applicant Therapeutic peptides are used to treat human diseases ranging from HIV to diabetes and have some of the best features of small molecule and recombinant protein dru ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Engineering Escherichia coli for sialylation of therapeutic proteins

    Amount: $1,197,523.00

    DESCRIPTION provided by applicant Glycoengineering is a clinically validated strategy to enhance the therapeutic properties of protein and peptide drugs This strategy involves the attachment and m ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  4. Multiplexed Protein and miRNA Biomarker-based Next-gen Test for Alzheimers Disease

    Amount: $197,758.00

    DESCRIPTION: Therapeutic peptides are used to treat human diseases ranging from HIV to diabetes and have some of the best features of small molecule and recombinant protein drugs. Therapeutic peptide ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. BOTTOM-UP GLYCOENGINEERING LIBRARY OF N-GLYCANS

    Amount: $299,450.00

    Glycans are directly involved in the pathology of many major diseases. Glycosylated biomolecules are involved in biological functions including cell signaling, cell growth, immunity, three-dimensiona ...

    SBIR Phase I 2013 Department of Health and Human Services
  6. Production of recombinant human glucocerebrosidase in Escherichia coli

    Amount: $175,860.00

    DESCRIPTION (provided by applicant): Gaucher's disease is the most common lysosomal storage disease in humans resulting in the harmful accumulation of fatty glucocerebroside in the spleen, liver, ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Engineering Escherichia coli for glycosylation of complex human proteins

    Amount: $1,608,039.00

    DESCRIPTION (provided by applicant): Escherichia coli was the host organism for production of the first approved recombinant protein therapeutic in 1982. We now know that most therapeutic proteins req ...

    SBIR Phase II 2011 Department of Health and Human Services
  8. Therapeutic antibody fragments from glycoengineered Escherichia coli

    Amount: $391,734.00

    DESCRIPTION (provided by applicant): Omalizumab (XolairTM) is a recombinant monoclonal anti-IgE antibody used in the fight against severe allergic asthma that generates 500 million per year. However, ...

    SBIR Phase I 2010 Department of Health and Human Services
  9. Conjugation of polysialic acid to biologics in glycoengineered Escherichia coli

    Amount: $199,020.00

    DESCRIPTION (provided by applicant): Biotherapeutics currently constitute a 70 billion market, but their clinical efficacy is often compromised by limitations arising from proteolytic degradation, up ...

    SBIR Phase I 2010 Department of Health and Human Services
  10. Humanizing N-linked glycosylation in Escherichia coli

    Amount: $115,988.00

    DESCRIPTION (provided by applicant): Protein-based therapeutics currently represent one in every four new drugs approved by the FDA and command a market in excess of 30 billion. The vast majority of ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government